Mathilde Bonnet-Duquennoy, Janine Papon, Florence Mishellany, Pierre Labarre, Jean-Luc Guerquin-Kern, Ting-Di Wu, Maryline Gardette, Jean Maublant, Frédérique Penault-Llorca, Elisabeth Miot-Noirault, Anne Cayre, Jean-Claude Madelmont, Jean-Michel Chezal, Nicole Moins
In recent years, there has been dramatic worldwide increase in incidence of malignant melanoma. Although localised disease is often curable by surgical excision, metastatic melanoma is inherently resistant to most treatments. In this context, targeted radionuclide therapy could be an efficient alternative. After pharmacomodulation study, we selected a quinoxaline derivative molecule (ICF01012) for its high, specific and long-lasting uptake in melanoma with rapid clearance from nontarget organs providing suitable dosimetry parameters for targeted radiotherapy...
August 1, 2009: International Journal of Cancer. Journal International du Cancer